Pharmacological Management of Anemia
Anemia is not a single disease, so its drug treatment depends entirely on the underlying mechanism: deficient production (iron, B12, folate, marrow failure), impaired erythropoietin response (chronic kidney disease, chronic inflammation), or increased destruction (hemolysis). Below is an organized rundown of agents used, based on Katzung's Basic and Clinical Pharmacology (16th ed.) supplemented with nephrology, hematology, and current guideline sources.
1. Iron Deficiency Anemia
Iron is required for heme synthesis; deficiency causes microcytic, hypochromic anemia and is the most common cause of chronic anemia worldwide.
Oral iron (first-line):
- Ferrous sulfate, ferrous gluconate, ferrous fumarate - cheap and effective; ferrous salts are absorbed best.
- Usual adult dose: 200-400 mg elemental iron/day (e.g., ferrous sulfate 325 mg tablets = 65 mg elemental iron, 2-4 tabs/day), continued 3-6 months after correcting the cause to replenish stores.
- Adverse effects: nausea, epigastric discomfort, constipation/diarrhea, black stools (harmless but can mask ongoing GI bleeding).
Parenteral iron (iron dextran, iron sucrose, sodium ferric gluconate complex, ferric carboxymaltose, ferumoxytol) - reserved for malabsorption, intolerance of oral iron, inflammatory bowel disease, CKD/dialysis patients on erythropoietin, or need for rapid repletion. Colloidal formulations release iron slowly to limit toxicity; adverse effects include hypersensitivity reactions, hypotension, and headache.
Iron toxicity/overload management:
-
Acute pediatric ingestion: whole bowel irrigation plus IV deferoxamine (chelator); activated charcoal does NOT bind iron.
-
Chronic overload (hemochromatosis, transfusion-dependent thalassemia): phlebotomy is most efficient when anemia is absent; otherwise deferoxamine (parenteral) or oral chelators deferasirox or deferiprone (monitor for agranulocytosis with deferiprone).
-
Katzung's Basic and Clinical Pharmacology, 16th ed., p. 927-933, 946
2. Megaloblastic Anemias (B12 and Folate Deficiency)
Vitamin B12 (cobalamin):
- Available as cyanocobalamin or hydroxocobalamin (preferred - more protein-bound, longer circulating).
- Parenteral: 100-1000 mcg IM daily/every other day for 1-2 weeks to replenish stores, then 100-1000 mcg IM monthly for life (pernicious anemia). If neurologic symptoms are present, give every 1-2 weeks for 6 months before switching to monthly.
- Oral 1000 mcg/day can be used if injections are refused/not tolerated; intranasal spray/gel is an option once in remission.
- Critical rule: never treat unexplained megaloblastic anemia with folic acid alone - it corrects the anemia but does not prevent (and may worsen) the neurologic damage of B12 deficiency.
Folic acid:
-
Oral folic acid 1 mg/day is sufficient in nearly all patients (parenteral rarely needed - well absorbed even with malabsorption).
-
Indicated for dietary deficiency, alcohol use disorder, pregnancy, hemolytic anemia, malabsorption, dialysis patients, and those on methotrexate/phenytoin/trimethoprim.
-
Also given as public-health supplementation to prevent neural tube defects.
-
Katzung's Basic and Clinical Pharmacology, 16th ed., p. 934-937, 946-947
3. Anemia of Chronic Kidney Disease / Chronic Disease - Erythropoiesis-Stimulating Agents (ESAs) and HIF-PH Inhibitors
Erythropoietin analogs: epoetin alfa, epoetin beta, darbepoetin alfa (longer half-life).
- Used for anemia of CKD, HIV patients on zidovudine, chemotherapy-induced anemia (hemoglobin <10 g/dL), and select low-risk myelodysplastic syndrome patients. Best response occurs when endogenous erythropoietin is disproportionately low (<100 IU/L).
- Iron stores must be adequate (often requires concurrent iron therapy) for ESAs to work.
- Toxicity: hypertension and thrombotic/cardiovascular events are the main risks; rare pure red cell aplasia from neutralizing antibodies (historically linked to a subcutaneous epoetin formulation). Methoxy PEG-epoetin beta should be avoided in chemotherapy-induced anemia due to increased mortality signal in trials.
- Illicit use in "blood doping" by athletes is banned and tested for.
Hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors - a newer oral class: roxadustat, daprodustat, vadadustat, molidustat. These stabilize HIF, increasing endogenous erythropoietin and improving iron utilization; developed following the 2019 Nobel Prize-winning hypoxia-sensing research. Used in dialysis and non-dialysis CKD anemia; roxadustat is banned by anti-doping authorities.
Note: the KDIGO 2026 Clinical Practice Guideline for Anemia in CKD (an update to the 2012 guideline) now provides consolidated, GRADE-based recommendations covering iron therapy, ESAs, and HIF-PH inhibitors in CKD anemia - worth checking for current hemoglobin targets and iron thresholds if managing a CKD patient.
- Katzung's Basic and Clinical Pharmacology, 16th ed., p. 940-942; Comprehensive Clinical Nephrology, 7th ed.; Brenner and Rector's The Kidney
4. Aplastic Anemia / Bone Marrow Failure
-
Immunosuppressive therapy: antithymocyte globulin (ATG) + cyclosporine ± glucocorticoids for patients ineligible for transplant.
-
Eltrombopag (thrombopoietin receptor agonist) added to standard immunosuppression improves hematologic response in severe aplastic anemia.
-
Allogeneic hematopoietic stem cell transplant (with ATG/cyclophosphamide conditioning) remains curative therapy in eligible (typically younger) patients, curing >95% of matched-sibling recipients under 40.
-
Harrison's Principles of Internal Medicine, 22nd ed.; Frameworks for Internal Medicine
5. Thrombopoietin Receptor Agonists and Other Growth Factors (supportive, not anemia-specific but part of the same drug class)
| Agent | Use |
|---|
| G-CSF (filgrastim, pegfilgrastim, tbo-filgrastim, lenograstim) | Chemotherapy-induced neutropenia, stem cell mobilization |
| GM-CSF (sargramostim) | Neutropenia, stem cell mobilization (less effective, more toxic than G-CSF) |
| Interleukin-11 (oprelvekin) | Chemotherapy-induced thrombocytopenia |
| Romiplostim, eltrombopag, avatrombopag, fostamatinib | Immune thrombocytopenia (and eltrombopag in aplastic anemia) |
6. Hemolytic Anemias
- Autoimmune hemolytic anemia: glucocorticoids (first-line), with rituximab or splenectomy for refractory cases (not primarily a "pharmacology of anemia" chapter topic but relevant clinically).
- Sickle cell disease: hydroxyurea increases fetal hemoglobin (HbF), reducing sickling and vaso-occlusive crises - it doesn't correct anemia through hematinic replacement but is the classic pharmacologic disease-modifying agent for this hemolytic anemia.
Summary logic for choosing therapy
- Confirm the mechanism (iron studies, B12/folate levels, reticulocyte count, renal function, marrow biopsy if indicated) before treating - empiric folic acid can mask B12 deficiency neurologically.
- Replace the specific deficient substrate (iron, B12, folate) rather than using ESAs when a nutritional cause is present.
- Reserve ESAs/HIF-PH inhibitors for anemia driven by relative erythropoietin deficiency (CKD, chemotherapy, certain MDS) after ensuring iron sufficiency.
- Use immunosuppression/transplant for marrow failure states (aplastic anemia).
- Address the disease-modifying option (hydroxyurea) for genetic hemolytic anemias like sickle cell disease.
Evidence check: A recent PubMed search for meta-analyses/systematic reviews in the past 2 years found mostly disease-specific reviews (e.g., preoperative anemia management in cardiac surgery, PMID 37932652) rather than a shift in the core drug classes above; no findings would meaningfully change this framework. Also worth flagging: the newly released KDIGO 2026 CKD anemia guideline may adjust specific hemoglobin targets, ferritin thresholds, and the role of HIF-PH inhibitors relative to ESAs - if the question involves CKD specifically, that update is worth reviewing directly.